Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage.
Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, Sconocchia G. Arriga R, et al. Among authors: sconocchia t, sconocchia g. Oncotarget. 2016 Jan 12;7(2):2070-9. doi: 10.18632/oncotarget.6529. Oncotarget. 2016. PMID: 26655503 Free PMC article.
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance.
Caratelli S, Sconocchia T, Arriga R, Coppola A, Lanzilli G, Lauro D, Venditti A, Del Principe MI, Buccisano F, Maurillo L, Ferrone S, Sconocchia G. Caratelli S, et al. Among authors: sconocchia t, sconocchia g. Front Immunol. 2017 Apr 27;8:457. doi: 10.3389/fimmu.2017.00457. eCollection 2017. Front Immunol. 2017. PMID: 28496440 Free PMC article. Review.
CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
Arriga R, Caratelli S, Lanzilli G, Ottaviani A, Cenciarelli C, Sconocchia T, Spagnoli GC, Iezzi G, Roselli M, Lauro D, Coppola A, Dotti G, Ferrone S, Sconocchia G. Arriga R, et al. Among authors: sconocchia t, sconocchia g. Int J Cancer. 2020 May 1;146(9):2531-2538. doi: 10.1002/ijc.32618. Epub 2019 Aug 30. Int J Cancer. 2020. PMID: 31396956 Free PMC article.
In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab.
Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, Cenciarelli C, Venditti A, Del Principe MI, Lauro D, Landoni E, Du H, Savoldo B, Ferrone S, Dotti G, Sconocchia G. Caratelli S, et al. Among authors: sconocchia t, sconocchia g. Int J Cancer. 2020 Jan 1;146(1):236-247. doi: 10.1002/ijc.32663. Epub 2019 Oct 12. Int J Cancer. 2020. PMID: 31479522 Free PMC article.
Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia.
Aureli A, Marziani B, Sconocchia T, Del Principe MI, Buzzatti E, Pasqualone G, Venditti A, Sconocchia G. Aureli A, et al. Among authors: sconocchia t. Cancers (Basel). 2021 Dec 13;13(24):6246. doi: 10.3390/cancers13246246. Cancers (Basel). 2021. PMID: 34944865 Free PMC article. Review.
Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment.
Sconocchia G, Lanzilli G, Cesarini V, Silvestris DA, Rezvani K, Arriga R, Caratelli S, Chen K, Dou J, Cenciarelli C, Toietta G, Baldari S, Sconocchia T, De Paolis F, Aureli A, Iezzi G, Irno Consalvo M, Buccisano F, Del Principe MI, Maurillo L, Venditti A, Ottaviani A, Spagnoli GC. Sconocchia G, et al. Among authors: sconocchia t. Life Sci Alliance. 2022 Oct 14;5(12):e202201590. doi: 10.26508/lsa.202201590. Print 2022 Dec. Life Sci Alliance. 2022. PMID: 36241426 Free PMC article.
18 results